Postoperative Atrial Fibrillation or Flutter Following Transcatheter or Surgical Aortic Valve Replacement: PARTNER 3 Trial

Bahira Shahim; S. Chris Malaisrie; Isaac George; Vinod H. Thourani; Angelo B. Biviano; Mark Russo; David L. Brown; Vasilis Babaliaros; Robert A. Guyton; Susheel K. Kodali; Tamim M. Nazif; Samir Kapadia; Philippe Pibarot; James M. McCabe; Mathew Williams; Philippe Genereux; Michael Lu; Xiao Yu; Maria Alu; John G. Webb; Michael J. Mack; Martin B. Leon; Ioanna Kosmidou

doi:10.1016/j.jcin.2021.05.026

Postoperative Atrial Fibrillation or Flutter Following Transcatheter or Surgical Aortic Valve Replacement: PARTNER 3 Trial

Bahira Shahim, S. Chris Malaisrie, Isaac George, Vinod H. Thourani, Angelo B. Biviano, Mark Russo, David L. Brown, Vasilis Babaliaros, Robert A. Guyton, Susheel K. Kodali, Tamim M. Nazif, Samir Kapadia, Philippe Pibarot, James M. McCabe, Mathew Williams, Philippe Genereux, Michael Lu, Xiao Yu, Maria Alu, John G. WebbMichael J. Mack, Martin B. Leon, Ioanna Kosmidou^*

^*Corresponding author for this work

Surgery, Cardiac Surgery Division

Research output: Contribution to journal › Article › peer-review

30 Scopus citations

Abstract

Objectives: The aim of this study was to assess the incidence and prognostic impact of early and late postoperative atrial fibrillation or flutter (POAF) in patients with severe aortic stenosis (AS) treated with transcatheter aortic valve replacement (TAVR) or surgical aortic valve replacement (SAVR). Background: There is an ongoing controversy regarding the incidence, recurrence rate, and prognostic impact of early (in-hospital) POAF and late (postdischarge) POAF in patients with AS undergoing TAVR or SAVR. Methods: In the PARTNER (Placement of Aortic Transcatheter Valve) 3 trial, patients with severe AS at low surgical risk were randomized to TAVR or SAVR. Analyses were performed in the as-treated population excluding patients with preexistent atrial fibrillation or flutter. Results: Among 781 patients included in the analysis, early POAF occurred in 152 (19.5%) (18 of 415 [4.3%] and 134 of 366 [36.6%] following TAVR and SAVR, respectively). Following discharge, 58 new or recurrent late POAF events occurred within 1 year following the index procedure in 55 of 781 patients (7.0%). Early POAF was not an independent predictor of late POAF following discharge (odds ratio: 1.04; 95% CI: 0.52-2.08; P = 0.90). Following adjustment, early POAF was not an independent predictor of the composite outcome of death, stroke, or rehospitalization (hazard ratio: 1.10; 95% CI: 0.64-1.92; P = 0.72), whereas late POAF was associated with an increased adjusted risk for the composite outcome (hazard ratio: 8.90; 95% CI: 5.02-15.74; P < 0.0001), irrespective of treatment modality. Conclusions: In the PARTNER 3 trial, early POAF was more frequent following SAVR compared with TAVR. Late POAF, but not early POAF, was significantly associated with worse outcomes at 2 years, irrespective of treatment modality.

Original language	English (US)
Pages (from-to)	1565-1574
Number of pages	10
Journal	JACC: Cardiovascular Interventions
Volume	14
Issue number	14
DOIs	https://doi.org/10.1016/j.jcin.2021.05.026
State	Published - Jul 26 2021

Funding

The PARTNER 3 trial was funded by Edwards Lifesciences. Dr Malaisrie is a consultant for Edwards Lifesciences, Medtronic, and Abbott. Dr George is a consultant for Edwards Lifesciences. Dr Thourani does research and is a consultant for Abbott Vascular, Allergen, Boston Scientific, CryoLife, Edwards Lifesciences, Gore Vascular, and JenaValve. Dr Babaliaros has received institutional research funding from Abbott, Edwards Lifesciences, and Medtronic; has received consulting fees from Edwards Lifesciences; and holds equity in Transmural Systems. Dr Kodali has received institutional research grants from Edwards Lifesciences, Medtronic, and Abbott; has received consulting fees from Abbott, Admedus, and Meril Life; and holds equity options from Biotrace Medical and Thubrikar Aortic Valve. Dr Nazif is a consultant for Edwards Lifesciences, Medtronic, and Boston Scientific. Dr Genereux has received consulting fees from Abbott Vascular, Abiomed, Boston Scientific, Cardinal Health, Cardiovascular Systems, Edwards Lifesciences, Medtronic, Opsens, Siemens, SoundBite Medical Solutions, Sig.Num, Saranas, Teleflex, and Tryton Medical; and has equity in Pi-Cardia, Sig.Num, SoundBite Medical Solutions, Saranas, and Puzzle Medical. Drs Lu and Yu are employees of Edwards Lifesciences. Ms Alu has received institutional research support (no direct compensation) from Abbott and Edwards Lifesciences. Dr Webb is a proctor and consultant for Edwards Lifesciences. Dr Mack has received institutional research support (no direct physician compensation) from Edwards Lifesciences. Dr Leon has received institutional research support from Edwards Lifesciences, Medtronic, Boston Scientific, and Abbott; and is a consultant or advisory board member for Medtronic, Boston Scientific, Gore, Meril Life, and Abbott. Dr Kosmidou has received institutional research support from Amgen; and is a consultant for Sanofi. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Keywords

atrial fibrillation
mortality
stroke
surgical aortic valve replacement
transcatheter aortic valve replacement

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

Access to Document

10.1016/j.jcin.2021.05.026

Cite this

Shahim, B., Malaisrie, S. C., George, I., Thourani, V. H., Biviano, A. B., Russo, M., Brown, D. L., Babaliaros, V., Guyton, R. A., Kodali, S. K., Nazif, T. M., Kapadia, S., Pibarot, P., McCabe, J. M., Williams, M., Genereux, P., Lu, M., Yu, X., Alu, M., ... Kosmidou, I. (2021). Postoperative Atrial Fibrillation or Flutter Following Transcatheter or Surgical Aortic Valve Replacement: PARTNER 3 Trial. JACC: Cardiovascular Interventions, 14(14), 1565-1574. https://doi.org/10.1016/j.jcin.2021.05.026

@article{83ad288d09934d27a8ef63e70acad603,

title = "Postoperative Atrial Fibrillation or Flutter Following Transcatheter or Surgical Aortic Valve Replacement: PARTNER 3 Trial",

abstract = "Objectives: The aim of this study was to assess the incidence and prognostic impact of early and late postoperative atrial fibrillation or flutter (POAF) in patients with severe aortic stenosis (AS) treated with transcatheter aortic valve replacement (TAVR) or surgical aortic valve replacement (SAVR). Background: There is an ongoing controversy regarding the incidence, recurrence rate, and prognostic impact of early (in-hospital) POAF and late (postdischarge) POAF in patients with AS undergoing TAVR or SAVR. Methods: In the PARTNER (Placement of Aortic Transcatheter Valve) 3 trial, patients with severe AS at low surgical risk were randomized to TAVR or SAVR. Analyses were performed in the as-treated population excluding patients with preexistent atrial fibrillation or flutter. Results: Among 781 patients included in the analysis, early POAF occurred in 152 (19.5%) (18 of 415 [4.3%] and 134 of 366 [36.6%] following TAVR and SAVR, respectively). Following discharge, 58 new or recurrent late POAF events occurred within 1 year following the index procedure in 55 of 781 patients (7.0%). Early POAF was not an independent predictor of late POAF following discharge (odds ratio: 1.04; 95% CI: 0.52-2.08; P = 0.90). Following adjustment, early POAF was not an independent predictor of the composite outcome of death, stroke, or rehospitalization (hazard ratio: 1.10; 95% CI: 0.64-1.92; P = 0.72), whereas late POAF was associated with an increased adjusted risk for the composite outcome (hazard ratio: 8.90; 95% CI: 5.02-15.74; P < 0.0001), irrespective of treatment modality. Conclusions: In the PARTNER 3 trial, early POAF was more frequent following SAVR compared with TAVR. Late POAF, but not early POAF, was significantly associated with worse outcomes at 2 years, irrespective of treatment modality.",

keywords = "atrial fibrillation, mortality, stroke, surgical aortic valve replacement, transcatheter aortic valve replacement",

author = "Bahira Shahim and Malaisrie, {S. Chris} and Isaac George and Thourani, {Vinod H.} and Biviano, {Angelo B.} and Mark Russo and Brown, {David L.} and Vasilis Babaliaros and Guyton, {Robert A.} and Kodali, {Susheel K.} and Nazif, {Tamim M.} and Samir Kapadia and Philippe Pibarot and McCabe, {James M.} and Mathew Williams and Philippe Genereux and Michael Lu and Xiao Yu and Maria Alu and Webb, {John G.} and Mack, {Michael J.} and Leon, {Martin B.} and Ioanna Kosmidou",

note = "Publisher Copyright: {\textcopyright} 2021 The Authors",

year = "2021",

month = jul,

day = "26",

doi = "10.1016/j.jcin.2021.05.026",

language = "English (US)",

volume = "14",

pages = "1565--1574",

journal = "JACC: Cardiovascular Interventions",

issn = "1936-8798",

publisher = "Elsevier Inc.",

number = "14",

}

Shahim, B, Malaisrie, SC, George, I, Thourani, VH, Biviano, AB, Russo, M, Brown, DL, Babaliaros, V, Guyton, RA, Kodali, SK, Nazif, TM, Kapadia, S, Pibarot, P, McCabe, JM, Williams, M, Genereux, P, Lu, M, Yu, X, Alu, M, Webb, JG, Mack, MJ, Leon, MB & Kosmidou, I 2021, 'Postoperative Atrial Fibrillation or Flutter Following Transcatheter or Surgical Aortic Valve Replacement: PARTNER 3 Trial', JACC: Cardiovascular Interventions, vol. 14, no. 14, pp. 1565-1574. https://doi.org/10.1016/j.jcin.2021.05.026

TY - JOUR

T1 - Postoperative Atrial Fibrillation or Flutter Following Transcatheter or Surgical Aortic Valve Replacement

T2 - PARTNER 3 Trial

AU - Shahim, Bahira

AU - Malaisrie, S. Chris

AU - George, Isaac

AU - Thourani, Vinod H.

AU - Biviano, Angelo B.

AU - Russo, Mark

AU - Brown, David L.

AU - Babaliaros, Vasilis

AU - Guyton, Robert A.

AU - Kodali, Susheel K.

AU - Nazif, Tamim M.

AU - Kapadia, Samir

AU - Pibarot, Philippe

AU - McCabe, James M.

AU - Williams, Mathew

AU - Genereux, Philippe

AU - Lu, Michael

AU - Yu, Xiao

AU - Alu, Maria

AU - Webb, John G.

AU - Mack, Michael J.

AU - Leon, Martin B.

AU - Kosmidou, Ioanna

PY - 2021/7/26

Y1 - 2021/7/26

N2 - Objectives: The aim of this study was to assess the incidence and prognostic impact of early and late postoperative atrial fibrillation or flutter (POAF) in patients with severe aortic stenosis (AS) treated with transcatheter aortic valve replacement (TAVR) or surgical aortic valve replacement (SAVR). Background: There is an ongoing controversy regarding the incidence, recurrence rate, and prognostic impact of early (in-hospital) POAF and late (postdischarge) POAF in patients with AS undergoing TAVR or SAVR. Methods: In the PARTNER (Placement of Aortic Transcatheter Valve) 3 trial, patients with severe AS at low surgical risk were randomized to TAVR or SAVR. Analyses were performed in the as-treated population excluding patients with preexistent atrial fibrillation or flutter. Results: Among 781 patients included in the analysis, early POAF occurred in 152 (19.5%) (18 of 415 [4.3%] and 134 of 366 [36.6%] following TAVR and SAVR, respectively). Following discharge, 58 new or recurrent late POAF events occurred within 1 year following the index procedure in 55 of 781 patients (7.0%). Early POAF was not an independent predictor of late POAF following discharge (odds ratio: 1.04; 95% CI: 0.52-2.08; P = 0.90). Following adjustment, early POAF was not an independent predictor of the composite outcome of death, stroke, or rehospitalization (hazard ratio: 1.10; 95% CI: 0.64-1.92; P = 0.72), whereas late POAF was associated with an increased adjusted risk for the composite outcome (hazard ratio: 8.90; 95% CI: 5.02-15.74; P < 0.0001), irrespective of treatment modality. Conclusions: In the PARTNER 3 trial, early POAF was more frequent following SAVR compared with TAVR. Late POAF, but not early POAF, was significantly associated with worse outcomes at 2 years, irrespective of treatment modality.

AB - Objectives: The aim of this study was to assess the incidence and prognostic impact of early and late postoperative atrial fibrillation or flutter (POAF) in patients with severe aortic stenosis (AS) treated with transcatheter aortic valve replacement (TAVR) or surgical aortic valve replacement (SAVR). Background: There is an ongoing controversy regarding the incidence, recurrence rate, and prognostic impact of early (in-hospital) POAF and late (postdischarge) POAF in patients with AS undergoing TAVR or SAVR. Methods: In the PARTNER (Placement of Aortic Transcatheter Valve) 3 trial, patients with severe AS at low surgical risk were randomized to TAVR or SAVR. Analyses were performed in the as-treated population excluding patients with preexistent atrial fibrillation or flutter. Results: Among 781 patients included in the analysis, early POAF occurred in 152 (19.5%) (18 of 415 [4.3%] and 134 of 366 [36.6%] following TAVR and SAVR, respectively). Following discharge, 58 new or recurrent late POAF events occurred within 1 year following the index procedure in 55 of 781 patients (7.0%). Early POAF was not an independent predictor of late POAF following discharge (odds ratio: 1.04; 95% CI: 0.52-2.08; P = 0.90). Following adjustment, early POAF was not an independent predictor of the composite outcome of death, stroke, or rehospitalization (hazard ratio: 1.10; 95% CI: 0.64-1.92; P = 0.72), whereas late POAF was associated with an increased adjusted risk for the composite outcome (hazard ratio: 8.90; 95% CI: 5.02-15.74; P < 0.0001), irrespective of treatment modality. Conclusions: In the PARTNER 3 trial, early POAF was more frequent following SAVR compared with TAVR. Late POAF, but not early POAF, was significantly associated with worse outcomes at 2 years, irrespective of treatment modality.

KW - atrial fibrillation

KW - mortality

KW - stroke

KW - surgical aortic valve replacement

KW - transcatheter aortic valve replacement

UR - http://www.scopus.com/inward/record.url?scp=85110207093&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85110207093&partnerID=8YFLogxK

U2 - 10.1016/j.jcin.2021.05.026

DO - 10.1016/j.jcin.2021.05.026

M3 - Article

C2 - 34294398

AN - SCOPUS:85110207093

SN - 1936-8798

VL - 14

SP - 1565

EP - 1574

JO - JACC: Cardiovascular Interventions

JF - JACC: Cardiovascular Interventions

IS - 14

ER -

Postoperative Atrial Fibrillation or Flutter Following Transcatheter or Surgical Aortic Valve Replacement: PARTNER 3 Trial

Abstract

Funding

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this